What is the equity of Geron this year?
Geron has equity of 247.95 M USD this year.
Geron Equity 2024
Geron Equity
247.95 M USD
Ticker
GERN
ISIN
US3741631036
WKN
902213
In 2024, Geron's equity was 247.95 M USD, a 209.94% increase from the 80 M USD equity in the previous year.
Geron Aktienanalyse
What does Geron do?
Geron Corp is a biopharmaceutical company headquartered in Menlo Park, California, founded in 1990. The company's goal is to develop innovative products and therapies that have the potential to combat serious diseases. Geron Corp specializes in the research of embryonic stem cells. The company is a pioneer in researching technologies for the use of stem cells and has made significant breakthroughs in the field of regenerative medicine. By developing new stem cell therapies, Geron Corp aims to improve the lives of patients with serious conditions such as cancer, Parkinson's disease, and spinal cord injuries. Geron Corp operates various business segments, including oncology, regenerative medicine, and RNA-based therapies. In the field of oncology, the company focuses on developing therapies for the treatment of cancer, particularly solid tumors. One of the most important developments is the drug Imetelstat, which aims to extend the telomeres of cancer cells by inhibiting the activity of telomerase. Imetelstat is currently in various clinical trials and has the potential to revolutionize the treatment of leukemia and other types of cancer. Another important business segment of Geron Corp is regenerative medicine, particularly the research of therapies for repairing spinal cord injuries. The company has made significant breakthroughs in this area and has a promising pipeline of products aimed at repairing damaged nerve cells in the spinal cord and restoring patients' mobility. Geron Corp is also a leading company in the field of RNA-based therapies. RNA-based therapies aim to regulate gene activity to treat diseases. The company has developed various innovative technologies aimed at accelerating and enhancing the development of RNA-based therapies. In recent years, Geron Corp has brought a variety of products to the market, including drugs for the treatment of spinal cord injuries, leukemia, and other types of cancer. The company has also formed partnerships with other leading companies in the biopharmaceutical industry to advance the development and commercialization of products. Overall, Geron Corp has made a significant contribution to the research and development of new technologies and therapies with the potential to improve the lives of millions of people. The company has a promising pipeline of products and is committed to further solidifying its position as a leading company in the biopharmaceutical industry. Geron ist eines der beliebtesten Unternehmen auf Eulerpool.com.Equity Details
Analyzing Geron's Equity
Geron's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Geron's equity is essential for assessing its financial health, stability, and value to shareholders.
Year-to-Year Comparison
Evaluating Geron's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.
Impact on Investments
Geron's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.
Interpreting Equity Fluctuations
Fluctuations in Geron’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.
Frequently Asked Questions about Geron stock
What was the equity of Geron compared to the previous year?
The equity of Geron has increased/decreased by 209.94% increased compared to the previous year.
What impact does a high equity have on investors of Geron?
A high equity is advantageous for investors of Geron as it is an indicator of the company's financial stability and its ability to manage risks and challenges.
What impact does low equity have on investors of Geron?
A low equity can be a risk for investors of Geron, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.
How does an increase in equity of Geron affect the company?
An increase in equity of Geron can strengthen the company's financial position and improve its ability to make investments in the future.
How does a reduction in the equity of Geron affect the company?
A reduction in equity of Geron can affect the financial situation of the company and lead to a higher dependence on debt capital.
What are some factors that influence the equity of Geron?
Some factors that can affect the equity of Geron include profits, dividend payments, capital increases, and acquisitions.
Why is the equity of Geron so important for investors?
The equity of Geron is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.
What strategic measures can Geron take to change the equity?
To change equity, Geron can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.
How much dividend does Geron pay?
Over the past 12 months, Geron paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Geron is expected to pay a dividend of 0 USD.
What is the dividend yield of Geron?
The current dividend yield of Geron is .
When does Geron pay dividends?
Geron pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Geron?
Geron paid dividends every year for the past 0 years.
What is the dividend of Geron?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Geron located?
Geron is assigned to the 'Health' sector.
Wann musste ich die Aktien von Geron kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Geron from 8/24/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 8/24/2024.
When did Geron pay the last dividend?
The last dividend was paid out on 8/24/2024.
What was the dividend of Geron in the year 2023?
In the year 2023, Geron distributed 0 USD as dividends.
In which currency does Geron pay out the dividend?
The dividends of Geron are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The Geron stock can be added to a savings plan with the following providers: Trade Republic
Andere Kennzahlen von Geron
Our stock analysis for Geron Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Geron Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
